MCID: ACS001
MIFTS: 56

Acoustic Neuroma

Categories: Cancer diseases, Ear diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Acoustic Neuroma

MalaCards integrated aliases for Acoustic Neuroma:

Name: Acoustic Neuroma 12 74 52 58 42 15 71
Vestibular Schwannoma 12 52 58 15
Cerebellopontine Angle Tumor 52 71
Acoustic Neurilemoma 52 58
Acoustic Neurinoma 52 58
Neurinoma of the Acoustic Nerve 52
Vestibular Neurilemmoma 12
Neuroma, Acoustic 43
Neuroma Acoustic 54
Acoustic Tumor 52

Characteristics:

Orphanet epidemiological data:

58
vestibular schwannoma
Prevalence: 1-9/100000 (Denmark),1-9/100000 (United States),1-9/1000000;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:12689
MeSH 43 D009464
NCIt 49 C3276
SNOMED-CT 67 126949007
ICD10 via Orphanet 33 D33.3
UMLS via Orphanet 72 C0027859
Orphanet 58 ORPHA252175
UMLS 71 C0027859 C0474740

Summaries for Acoustic Neuroma

MedlinePlus : 42 An acoustic neuroma is a benign tumor that develops on the nerve that connects the ear to the brain. The tumor usually grows slowly. As it grows, it presses against the hearing and balance nerves. At first, you may have no symptoms or mild symptoms. They can include Loss of hearing on one side Ringing in ears Dizziness and balance problems The tumor can also eventually cause numbness or paralysis of the face. If it grows large enough, it can press against the brain, becoming life-threatening. Acoustic neuroma can be difficult to diagnose, because the symptoms are similar to those of middle ear problems. Ear exams, hearing tests, and scans can show if you have it. If the tumor stays small, you may only need to have it checked regularly. If you do need treatment, surgery and radiation are options. If the tumors affect both hearing nerves, it is often because of a genetic disorder called neurofibromatosis. NIH: National Institute on Deafness and Communication Disorders

MalaCards based summary : Acoustic Neuroma, also known as vestibular schwannoma, is related to neurofibromatosis and schwannomatosis 1, and has symptoms including seizures, tremor and back pain. An important gene associated with Acoustic Neuroma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are MicroRNAs in cancer and Cytoskeletal Signaling. The drugs Anti-Bacterial Agents and Gentamicins have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are Increased proliferation and growth/size/body region

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 252175 Definition Vestibular schwannoma is a rare tumor of the posterior fossa originating in the Schwann cells of the vestibular transitional zone of the vestibulocochlear nerve that can be benign, small, slow growing and asymptomatic or large, faster growing and aggressive and potentially fatal, presenting with symptoms of hearing and balance impairment, vertigo, ataxia , headache and fifth, sixth or seventh cranial nerve dysfunction and facial numbness. Visit the Orphanet disease page for more resources.

Wikipedia : 74 A vestibular schwannoma (VS) is a benign primary intracranial tumor of the myelin-forming cells of the... more...

Related Diseases for Acoustic Neuroma

Diseases related to Acoustic Neuroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 386)
# Related Disease Score Top Affiliating Genes
1 neurofibromatosis 33.3 RDX NF2 NF1
2 schwannomatosis 1 32.8 SMARCB1 NF2
3 neurofibromatosis, type ii 32.8 RDX NF2 NF1 MSN EZR ERBB3
4 facial paralysis 31.3 TGFB1 NF2 CRLF1
5 meniere disease 31.2 AQP6 AQP4 AQP1
6 hydrocephalus 31.0 TGFB1 SMARCB1 AQP4 AQP1
7 benign ependymoma 30.9 NF2 NF1 MGMT
8 secretory meningioma 30.7 SMARCB1 NF2
9 communicating hydrocephalus 30.7 TGFB1 AQP4 AQP1
10 cerebellopontine angle tumor 30.6 NF2 CRLF1
11 neuroma 30.6 TGFB1 SMARCB1 POLB NF2 NF1 MGMT
12 pathologic nystagmus 30.5 RDX MSN EZR
13 otosclerosis 30.4 TGFB1 NF2 CRLF1
14 monosomy 22 30.4 SMARCB1 NF2
15 spinal meningioma 30.4 SMARCB1 NF2 NF1 LZTR1
16 olfactory groove meningioma 30.4 NF2 LZTR1
17 cellular schwannoma 30.3 NF2 NF1
18 arachnoiditis 30.2 CRLF1 AQP4
19 grade iii astrocytoma 30.2 PCNA NF1 MGMT
20 meningioma, radiation-induced 30.1 SMARCB1 RDX PCNA NF2 MSN EZR
21 obstructive hydrocephalus 29.8 NF2 NF1 CRLF1 AQP4 AQP1
22 labyrinthitis 29.7 NF2 CRLF1
23 basal cell nevus syndrome 29.7 SMARCB1 NF2 NF1
24 meningioma, familial 29.5 SMARCB1 RDX PCNA NF2 NF1 MSN
25 brain stem infarction 29.4 LZTR1 CRLF1
26 neurilemmoma of the fifth cranial nerve 29.4 NF2 LZTR1 CRLF1
27 neurilemmomatosis 29.3 SMARCB1 NF2 NF1 LZTR1
28 neurilemmoma 29.2 SMARCB1 RDX NF2 NF1 MSN MIR96
29 gliosarcoma 29.0 NF1 MGMT LZTR1
30 brain cancer 29.0 SMARCB1 NF2 NF1 MGMT EZR AQP4
31 neurofibromatosis, type i 11.9
32 schwannomatosis 2 11.7
33 neurofibromatosis, type iv, of riccardi 11.5
34 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 11.0
35 sensorineural hearing loss 10.8
36 branchiootic syndrome 1 10.8
37 cerebrospinal fluid leak 10.7
38 lymphoplasmacyte-rich meningioma 10.7
39 headache 10.6
40 trigeminal neuralgia 10.5
41 ataxia and polyneuropathy, adult-onset 10.5
42 subependymoma 10.5 AQP4 AQP1
43 dysferlinopathy 10.5 AQP4 AQP1
44 47,xyy 10.4
45 meningitis 10.4
46 epithelioid neurofibroma 10.4 NF2 NF1
47 glioma 10.4
48 glial tumor 10.4
49 plexiform schwannoma 10.4 NF2 NF1
50 bullous keratopathy 10.4 TGFB1 AQP4 AQP1

Graphical network of the top 20 diseases related to Acoustic Neuroma:



Diseases related to Acoustic Neuroma

Symptoms & Phenotypes for Acoustic Neuroma

UMLS symptoms related to Acoustic Neuroma:


seizures, tremor, back pain, headache, syncope, tinnitus, pain, chronic pain, sciatica, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder, sleeplessness

GenomeRNAi Phenotypes related to Acoustic Neuroma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Acoustic Neuroma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 ABCA2 APEX1 AQP1 AQP4 ERBB3 EZR
2 homeostasis/metabolism MP:0005376 10.32 ABCA2 APEX1 AQP1 AQP4 ERBB3 LZTR1
3 mortality/aging MP:0010768 10.31 ABCA2 APEX1 AQP1 AQP4 CRLF1 ERBB3
4 behavior/neurological MP:0005386 10.3 ABCA2 AQP1 AQP4 CRLF1 ERBB3 NF1
5 hematopoietic system MP:0005397 10.27 AQP1 AQP4 CRLF1 EZR LZTR1 MSN
6 endocrine/exocrine gland MP:0005379 10.24 APEX1 AQP1 AQP4 ERBB3 MGMT NF1
7 immune system MP:0005387 10.2 APEX1 AQP4 ERBB3 EZR MSN NF1
8 nervous system MP:0003631 10.1 ABCA2 AQP1 AQP4 CRLF1 ERBB3 MGMT
9 digestive/alimentary MP:0005381 10.09 AQP4 ERBB3 EZR NF1 POLB SMARCB1
10 hearing/vestibular/ear MP:0005377 9.99 AQP1 AQP4 NF1 NF2 POLB RDX
11 liver/biliary system MP:0005370 9.98 APEX1 NF1 NF2 POLB RDX SMARCB1
12 neoplasm MP:0002006 9.91 APEX1 ERBB3 MGMT NF1 NF2 SMARCB1
13 reproductive system MP:0005389 9.81 ABCA2 APEX1 AQP1 NF1 NF2 PCNA
14 renal/urinary system MP:0005367 9.8 AQP1 AQP4 AQP6 NF1 NF2 POLB
15 respiratory system MP:0005388 9.61 AQP1 AQP4 ERBB3 MGMT MSN NF1
16 vision/eye MP:0005391 9.23 AQP1 AQP4 AQP6 NF1 NF2 POLB

Drugs & Therapeutics for Acoustic Neuroma

Drugs for Acoustic Neuroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4
2 Gentamicins Phase 4
3 Anti-Infective Agents Phase 4
4
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
5
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
8 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
9
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
10 Anti-Inflammatory Agents Phase 3
11 Methylprednisolone Acetate Phase 3
12 Hormones Phase 3
13 Antiemetics Phase 3
14 Neuroprotective Agents Phase 3
15 Hormone Antagonists Phase 3
16 glucocorticoids Phase 3
17 Protective Agents Phase 3
18
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
19
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
20
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
21
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
22
Betahistine Approved, Investigational Phase 2 5638-76-6 2366
23
Bevacizumab Approved, Investigational Phase 2 216974-75-3
24
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
25
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
26
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
27 diuretics Phase 2
28 Endostatins Phase 2 71581480
29 Analgesics, Non-Narcotic Phase 2
30 Fibrinolytic Agents Phase 2
31 Analgesics Phase 2
32 Antipyretics Phase 2
33 Platelet Aggregation Inhibitors Phase 2
34 Cyclooxygenase Inhibitors Phase 2
35 Antirheumatic Agents Phase 2
36 Anti-Inflammatory Agents, Non-Steroidal Phase 2
37 Pharmaceutical Solutions Phase 2
38 Angiogenesis Inhibitors Phase 2
39 Antineoplastic Agents, Immunological Phase 2
40 Immunosuppressive Agents Phase 2
41 Immunologic Factors Phase 2
42 Protein Kinase Inhibitors Phase 2
43 Immunoglobulins Phase 2
44 Antibodies Phase 2
45 Immunoglobulins, Intravenous Phase 2
46 Antibodies, Monoclonal Phase 2
47 Mitogens Phase 2
48 Endothelial Growth Factors Phase 2
49
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
50
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function Suspended NCT02415257 Phase 4 Gentamicin
2 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With Definite Remaining Vestibular Function Suspended NCT02379754 Phase 4 Gentamicins
3 Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-pontine Angle Surgery Completed NCT00438087 Phase 3 methylprednisolone
5 Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
6 Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) Unknown status NCT02819479 Phase 2 25% Mannitol;Low-dose Intra-arterial Bevacizumab
7 A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Completed NCT01490476 Phase 2 RAD001
8 Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping Completed NCT02104323 Phase 2 Endostatin
9 Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma Completed NCT01207687 Phase 2
10 Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors Completed NCT00973739 Phase 2 Lapatinib
11 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
12 Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas Recruiting NCT03079999 Phase 2 Aspirin;Placebo
13 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
14 Kan tumorvækst Forudsiges Ved RGD-PET/MR af Vestibularis Schwannomer? Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
15 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
16 Multicenter Randomized Controlled Phase 2 Trial to Evaluate AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS) Recruiting NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
17 A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
18 Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT04283669 Phase 2 Crizotinib
19 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
20 Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation Active, not recruiting NCT01767792 Phase 2 Bevacizumab
21 Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT02129647 Phase 2 Axitinib
22 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Not yet recruiting NCT04351373 Phase 2 intravenous fluorescein sodium
23 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Not yet recruiting NCT04374305 Phase 2 Brigatinib
24 A Phase II Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
25 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
26 Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Recruiting NCT03542773 Phase 1 18F-DCFPyL Injection
27 Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma (Acoustic Neuroma) Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
28 Response Prediction After Gamma Knife Surgery (GKS) in Patients With Vestibular Schwannoma Using Dynamic Contrast-Enhanced (DCE) MR Imaging Unknown status NCT03097822
29 Evaluation of the Influence of Psychological Factors on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT01743248
30 Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI Unknown status NCT03593577
31 Assessment of the Preoperative Vestibular Rehabilitation Effectiveness on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT02275325
32 Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery Unknown status NCT03520829
33 NF2 Natural History Consortium Unknown status NCT00004483
34 Consequence of Unilateral Vestibular Loss on Visual Abilities Unknown status NCT03581331
35 Taste Disorders in Middle Ear Disease and After Middle Ear Surgery Unknown status NCT01584011
36 Assessment of Visual Sensitivity, Psychiatric Profile and Quality of Life Following Vestibular Schwannoma Surgery in Patients Prehabituated by Chemical Vestibular Ablation Completed NCT03638310
37 Vestibular Evaluation Before and After Treatment of Vestibular Schwannoma. Comparison of Gamma Knife Radiosurgery and Microsurgical Resection Completed NCT03670589
38 Whole Exome Sequencing (WES) of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data Completed NCT03210285
39 Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Completed NCT02309099
40 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma With Pretreatment Prehabituation by Chemical Vestibular Ablation Completed NCT02963896 gentamicin
41 Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas Completed NCT00863122 Early Phase 1 lapatinib
42 Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas Completed NCT01880749 Early Phase 1 RAD001
43 Recovery of Visual Acuity in Vestibular Deficits Completed NCT00411216
44 Vasopressin and V2 Receptor in Meniere's Disease Completed NCT00599560
45 A Case-Referent Study of Brain Tumors in Adults Completed NCT00339300
46 Using Positron Emission Tomography (PET) to Predict Intracranial Tumor Growth in Neurofibromatosis Type II (NF2) Patients Completed NCT01222728
47 Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus Completed NCT00329524
48 A Family Study of Adults With Glioma Completed NCT00339352
49 Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma: A Longitudinal Study of Natural History Completed NCT01951365
50 New Diagnosis Of Vestibular Vertigo With Functional MRI Completed NCT00593216

Search NIH Clinical Center for Acoustic Neuroma

Cochrane evidence based reviews: neuroma, acoustic

Genetic Tests for Acoustic Neuroma

Anatomical Context for Acoustic Neuroma

MalaCards organs/tissues related to Acoustic Neuroma:

40
Brain, Testes, Bone, Pituitary, Endothelial, Temporal Lobe, Lung

Publications for Acoustic Neuroma

Articles related to Acoustic Neuroma:

(show top 50) (show all 4825)
# Title Authors PMID Year
1
Orofacial pain secondary to acoustic neuroma-A case report. 42 61
32384226 2020
2
Solitary fibrous tumor/hemangiopericytoma in the cerebellopontine angle mimicking vestibular schwannoma: A case report and literature review. 61 42
32221091 2020
3
Laser Interstitial Thermotherapy for Treatment of Symptomatic Peritumoral Edema After Radiosurgery for Meningioma. 42
32001396 2020
4
BDNF mRNA expression is significantly upregulated in vestibular schwannomas and correlates with proliferative activity. 61 54
19937367 2010
5
Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. 54 61
20195187 2010
6
Pathogenesis of vestibular schwannoma in ring chromosome 22. 54 61
19772601 2009
7
[Expression of S518 phosphorylated Merlin and its interaction with CD44 in vestibular schwannoma]. 61 54
19141242 2008
8
Compensative shuttling of merlin to phosphorylation on serine 518 in vestibular schwannoma. 61 54
17989580 2008
9
Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression. 61 54
17429338 2007
10
[Neurotrophic factor expression in vestibular schwannoma. An overview]. 54 61
16612755 2006
11
[Expression and localization of merlin in vestibular schwannoma]. 61 54
17007372 2006
12
Expression of ABCA2 protein in human vestibular schwannoma and peripheral nerve. 61 54
15850583 2005
13
Co-expression of transforming growth factor-beta1 and glial cell line-derived neurotrophic factor in vestibular schwannoma. 61 54
15129118 2004
14
Gene discovery using a human vestibular schwannoma cDNA library constructed from a patient with neurofibromatosis type 2 (NF2). 61 54
12646839 2003
15
Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. 54 61
11349767 2001
16
Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. 54 61
10024671 1999
17
Immunoblotting analysis of schwannomin/merlin in human schwannomas. 54 61
9752976 1998
18
Nerve growth factor receptor expression in heterotransplanted vestibular schwannoma in athymic nude mice. 61 54
8820351 1996
19
Molecular genetic analysis of the mechanism of tumorigenesis in acoustic neuroma. 54 61
8217082 1993
20
Case-control study on occupational exposure to extremely low-frequency electromagnetic fields and the association with acoustic neuroma. 61
32422481 2020
21
Refractory communicating hydrocephalus after radiation for small vestibular schwannoma with asymptomatic ventriculomegaly: A case report. 61
32435322 2020
22
Rising Incidence of Sporadic Vestibular Schwannoma: True Biological Shift Versus Simply Greater Detection. 61
32150020 2020
23
Management of sporadic vestibular schwannoma with contralateral nonserviceable hearing. 61
31643090 2020
24
Clinical outcomes of resecting scarpa's ganglion during vestibular schwannoma surgery. 61
32284286 2020
25
Sporadic vestibular schwannoma: a molecular testing summary. 61
32576656 2020
26
Delayed pseudoprogression of a vestibular schwannoma postradiosurgery. 61
32308777 2020
27
The oblique occipital sinus - implications in posterior fossa approaches. 61
32317189 2020
28
Implementation of model explainability for a basic brain tumor detection using convolutional neural networks on MRI slices. 61
32500277 2020
29
Combining Stereoscopic Video and Virtual Reality Simulation to Maximize Education in Lateral Skull Base Surgery. 61
32180502 2020
30
Suction Spatula for Surgery of Vestibular Schwannomas in Supine Position: Technical Note. 61
32147546 2020
31
National Trends in Surgical Resection of Vestibular Schwannomas. 61
32571146 2020
32
Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality. 61
32548671 2020
33
Time-based Assessment of Hearing Preservation Rates After Microsurgical Resection of Vestibular Schwannomas: A Systematic Review. 61
32150025 2020
34
Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology. 61
32565280 2020
35
Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2. 61
32150022 2020
36
Ipsilateral Cochlear Implantation in the Presence of Observed and Irradiated Vestibular Schwannomas. 61
32551844 2020
37
Jugular Paraganglioma and Bilateral Vestibular Schwannoma Presenting to an Acute Ophthalmology Service. 61
31842148 2020
38
Trends in hearing rehabilitation use among vestibular schwannoma patients. 61
31603544 2020
39
Comparison of translabyrinthine and retrosigmoid approach for treating vestibular schwannoma: A meta-analysis. 61
32540713 2020
40
Early life-threating enlargement of a vestibular schwannoma after gamma knife radiosurgery. 61
32504117 2020
41
Hearing Preservation Outcomes and Prognostic Factors in Acoustic Neuroma Surgery: Predicting Cutoffs. 61
32118808 2020
42
Exclusive surgical treatment for vestibular schwannoma regrowth or recurrence: A meta-analysis of the literature. 61
32146233 2020
43
Longitudinal Radiographic Outcomes of Vestibular Schwannoma in Single and Fractionated Stereotactic Radiosurgery: A Retrospective Cohort Study. 61
32500007 2020
44
Use of a compact high-definition two-dimensional exoscope in surgical treatment of large vestibular schwannoma. 61
32490607 2020
45
Effect of Vestibular Schwannoma Size and Nerve of Origin on Posterior External Auditory Canal Sensation: A Prospective Observational Study. 61
32569140 2020
46
Outcome and toxicity analysis of single dose stereotactic radiosurgery in vestibular schwannoma based on the Koos grading system. 61
32518238 2020
47
Comparison of test results from two separate video head impulse test systems in a cohort of patients diagnosed with a unilateral vestibular schwannoma. 61
32564123 2020
48
Video Head Impulse Test Results in Patients With a Vestibular Schwannoma-Sensitivity and Correlation With Other Vestibular System Function Tests, Hearing Acuity, and Tumor Size. 61
32118807 2020
49
What Clinicians Should Consider to Determine a More Beneficial Treatment Strategy for Small to Medium Sized Vestibular Schwannoma With Serviceable Hearing: A Single Surgeon's Long-term Outcome of Microsurgery and Gamma Knife Radiosurgery. 61
32569150 2020
50
Pediatric vestibular schwannomas: case series and a systematic review with meta-analysis. 61
32470932 2020

Variations for Acoustic Neuroma

Expression for Acoustic Neuroma

Search GEO for disease gene expression data for Acoustic Neuroma.

Pathways for Acoustic Neuroma

Pathways related to Acoustic Neuroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.25 RDX MIR96 EZR ERBB3
2 12.22 RDX NF2 MSN EZR
3 11.7 NF2 NF1 MGMT
4 11.67 TGFB1 RDX MSN EZR ERBB3
5 11.54 TGFB1 AQP4 AQP1 APEX1
6
Show member pathways
11.44 RDX MSN EZR
7 11.23 RDX PCNA NF2 MSN EZR
8 11.11 RDX MSN EZR
9 10.95 TGFB1 NF1 EZR
10 10.71 TGFB1 RDX MSN EZR ERBB3

GO Terms for Acoustic Neuroma

Cellular components related to Acoustic Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 9.72 MSN EZR ERBB3 AQP4 AQP1
2 ruffle GO:0001726 9.65 RDX NF2 EZR
3 cell periphery GO:0071944 9.58 RDX MSN EZR
4 filopodium GO:0030175 9.56 RDX NF2 MSN EZR
5 uropod GO:0001931 9.46 MSN EZR
6 microvillus GO:0005902 9.46 TGFB1 RDX MSN EZR
7 invadopodium GO:0071437 9.43 MSN EZR
8 apical plasma membrane GO:0016324 9.43 RDX MSN EZR ERBB3 AQP6 AQP1
9 cell tip GO:0051286 9.37 RDX EZR
10 apical part of cell GO:0045177 9.02 RDX NF2 MSN EZR AQP1

Biological processes related to Acoustic Neuroma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.01 TGFB1 RDX MSN EZR ERBB3
2 heart development GO:0007507 9.92 TGFB1 PCNA NF1 ERBB3
3 DNA repair GO:0006281 9.91 SMARCB1 POLB PCNA MGMT APEX1
4 regulation of cell proliferation GO:0042127 9.88 TGFB1 NF2 NF1 ERBB3
5 response to drug GO:0042493 9.85 TGFB1 MGMT AQP1 APEX1 ABCA2
6 wound healing GO:0042060 9.81 TGFB1 NF1 ERBB3
7 cellular response to hydrogen peroxide GO:0070301 9.74 PCNA AQP1 APEX1
8 cellular response to cAMP GO:0071320 9.71 EZR AQP1 APEX1
9 establishment of epithelial cell apical/basal polarity GO:0045198 9.65 MSN EZR
10 lymph node development GO:0048535 9.65 TGFB1 POLB
11 microvillus assembly GO:0030033 9.64 RDX EZR
12 negative regulation of cell-cell adhesion GO:0022408 9.64 TGFB1 NF2
13 protein kinase A signaling GO:0010737 9.63 RDX EZR
14 lens fiber cell differentiation GO:0070306 9.62 TGFB1 NF2
15 response to cholesterol GO:0070723 9.61 TGFB1 ABCA2
16 salivary gland morphogenesis GO:0007435 9.6 TGFB1 POLB
17 multicellular organismal water homeostasis GO:0050891 9.59 AQP4 AQP1
18 gland morphogenesis GO:0022612 9.58 MSN EZR
19 regulation of cell size GO:0008361 9.58 RDX MSN EZR
20 cellular water homeostasis GO:0009992 9.56 AQP4 AQP1
21 negative regulation of neuroblast proliferation GO:0007406 9.55 TGFB1 NF1
22 establishment of endothelial barrier GO:0061028 9.54 RDX MSN EZR
23 base-excision repair, gap-filling GO:0006287 9.52 POLB PCNA
24 water transport GO:0006833 9.5 AQP6 AQP4 AQP1
25 membrane to membrane docking GO:0022614 9.49 MSN EZR
26 carbon dioxide transport GO:0015670 9.48 AQP6 AQP1
27 base-excision repair, base-free sugar-phosphate removal GO:0006286 9.43 POLB APEX1
28 positive regulation of cellular protein catabolic process GO:1903364 9.43 RDX MSN EZR
29 positive regulation of early endosome to late endosome transport GO:2000643 9.33 RDX MSN EZR
30 positive regulation of protein localization to early endosome GO:1902966 9.13 RDX MSN EZR
31 regulation of organelle assembly GO:1902115 8.8 RDX MSN EZR

Molecular functions related to Acoustic Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 damaged DNA binding GO:0003684 9.43 POLB PCNA APEX1
2 channel activity GO:0015267 9.33 AQP6 AQP4 AQP1
3 DNA-(apurinic or apyrimidinic site) endonuclease activity GO:0003906 9.32 POLB APEX1
4 cytoskeletal protein binding GO:0008092 9.26 RDX NF2 MSN EZR
5 water channel activity GO:0015250 8.8 AQP6 AQP4 AQP1

Sources for Acoustic Neuroma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....